Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the clinical-stage biopharmaceutical company's 2025 results and progress since then, highlighting a busy period for the company, with its lead POLB-001 trial now fully prepared to begin across six UK sites. The trial targets prevention of cytokine release syndrome - a serious complication of cancer immunotherapies - with patient screening imminent and interim data expected this summer. FDA orphan drug designation adds market exclusivity and financial incentives, while independent US payer research confirms multi-billion-dollar commercial potential and insurer willingness to reimburse. Partnering discussions with large and mid-sized pharma are intensifying ahead of the data readout. Skillington also flagged progress on an oral GLP-1 programme, with a proof-of-concept trial targeted for 2026. For more insights and interviews like this, visit Proactive’s YouTube ...